Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2023-04-21 Regulatory Filings
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and is signed by the CEO. The content is a formal regulatory communication related to the registration process for securities, not a financial report or detailed filing. The document length is short (1277 characters) and it is a request letter, not a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-04-21 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from an underwriter withdrawing a prior letter related to a Registration Statement on Form S-1 withdrawal request for acceleration of effective date. It is a correspondence related to a regulatory filing process, specifically concerning a registration statement withdrawal and acceleration request. The document is short (929 characters) and does not contain financial data, report content, or detailed financial statements. It is not a report itself but a regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and correspondence that do not fit other specific categories.
2023-04-21 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from the CEO of MAIA Biotechnology, Inc. to the SEC withdrawing a prior request for acceleration of the effective date of a Registration Statement on Form S-1. It is correspondence related to regulatory filings and does not contain financial data, report content, or detailed financial statements. The document is short (1054 characters) and serves as a formal communication rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other categories.
2023-04-21 English
PRIMARY DOCUMENT
Director's Dealing
2023-04-21 English
FWP
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433 under a Registration Statement No. 333-269606. It is a Free Writing Prospectus (FWP) related to a proposed public offering of shares by MAIA Biotechnology, Inc. The text includes disclaimers about the registration statement, forward-looking statements, and investment overview, typical of offering documents. It references a Registration Statement on Form S-1 and preliminary prospectus dated April 19, 2023. The content focuses on the offering, pipeline, clinical trials, and safety data, but does not contain financial statements or earnings data. This is a type of prospectus document used in capital raising activities, specifically a Free Writing Prospectus, which is a form of offering communication. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Since this document is a Free Writing Prospectus related to a public offering and fundraising, it fits best under CAP. The document length is substantial and contains detailed information about the offering and related clinical data, not just a brief announcement or regulatory filing. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2023-04-20 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is a Form S-1/A (Amendment No. 2) registration statement filed with the U.S. Securities and Exchange Commission (SEC) by MAIA Biotechnology, Inc. The S-1 form is used for registration of securities for an initial public offering or other public offerings. The text includes detailed information about the offering, company background, risk factors, management discussion, and financial statements index. It is not an annual report, earnings release, or any other financial report but a registration statement for securities offering. This type of filing is not explicitly listed in the provided categories, but it is a regulatory filing related to securities registration. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-04-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.